In early July 2022, it was announced that DiscoveryBioMed - an active and well funded SBIR Awardee from soon after the firm was founded -- had been acquired by St Charles MO-based Eurofins Discovery. DiscoveryBioMed, Inc. (aka Discovery BioMed, Inc. and DBM) is a life sciences, biotech organized around integrating biologically- and disease-relevant human cell cultures and lines into all relevant steps in the Drug Discovery Critical Path. The firm's founder being a physiologist had enabled DBM to specialize in multiplexed bioassays of targets and phenotypes using both mono- and multi-culture designs for primary Drug Discovery, as well as, hit-to-lead validation of existing hit-to-lead assets. Complementing its Drug Discovery efforts, DBM specializes in custom cell culture and engineering and implementation of such cells at any and all inflections points within the Critical Path. DBMâs drug discovery efforts have been focused on Cystic Fibrosis, Hyperproliferative Disorders (Polycystic Kidney Disease) and Diabetes/Obesity
